Bioequivalence Assessment of Triamcinolone Tablets in Healthy Male Human Volunteers

  • Pyo, Hee-Soo (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) ;
  • Jang, Moon-Sun (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) ;
  • Chung, Youn-Bok (College of Pharmacy, Chungbuk National University) ;
  • Kwon, Oh-Seung (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology)
  • 발행 : 2002.09.01


The bioequivalence of two 4 mg triamcinolone tablets (Dong-Kwang Triamcinolone$\textregistered$ vs. Wyeth Korea Ledercoat$\textregistered$) was assessed in healthy male volunteers after oral administration of 16mg triamcinolone in a randomized crossover study. Blood samples were collected at specified time intervals, and plasma was analyzed for triamcinolone using a validated HPLC method. The pharmacokinetic parameters of $T_{max}$, $C_{max}$, $AUC_{0\longrightarrowlast}$, $AUC_{0\longrightarrowinf}$ and $T_{1/2, \beta} were determined from plasma concentration-time profile of two formulations. The pharmacokinetic parameters were statistically compared to evaluate bioequivalence between two formulations, according to Korea Food and Drug Administration Guideline. The analysis of variance did not show any significant difference between the two formulations and 90% confidence limits fell within the acceptable range (80-120%) for bioequivalence. Based on these data it was concluded that the two products showed comparable pharmacokinetic profiles and that the Dong-Kwang triamcinlone$\textregistered$ tablet is bioequivalent to the Wyeth Korea Ledercoat$\textregistered$ tablet.



  1. Argenli, D., Jensen, B. K., Hensel, R., Bordeaux, K., Schleimer, R., Bickel, C. and Heald, D. (2000a). A mass balance study to evaluate the biotransformation and excretion of '$^1^4C$'-triamci- nolone acetonide following oral administration. J. Clin. Phar- macol., 40(7), 770-780
  2. Argenti, D., Shah, B. and Heald, D. (2000b). A study comparing the clinical pharmacokinetics, Pharmacodynamics, and tolera- bility of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhala- tion administration. J. Clin. Pharmacol., 40(5), 516-526
  3. Carey, R. M. (1997). The changing clinical spectrum of adrenal insufficiency. Ann. Intern. Med. 127, 1103-1105
  4. Derendorf, H., Hochhaus, G., Rohatagi, S., Mollmann, H., Barth, J., Sourgens, H. and Erdmann, M. (1995). Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J. Clin. Pharmacol., 35(3), 302-305
  5. EC(1991). European Community, Investigation of Bioavailabil- ity and Bioequivalence, The Rules Governing Medicinal Prod- ucts in European Community, Vol. III, 149-169 (Addendum 2)
  6. FDA (2001). Guidancc for Industry, Statistical approaches to establishing bioequivalence. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Office of Training and Communication, Division of Communications Management, Rockville, MD, January
  7. Hochhaus, G., Portner, M., Barth, J., Mollmann, H. and Rohde wald, P. (1990). Oral bioavailability of triamcinolone tablets and triamcinolone diacetate suspension. Pharmaceutical Research, 7, 558-560
  8. KFDA (1998). Korea Food and Drug Administration, The guide line for bioequivalence test, Act No. 1998-86
  9. KFDA (2001). Korea Food and Drug Administration, The gide line for bioequivalence test; Act No. 2001-57
  10. Lee. Y. J., Choi, J. H., Song, S. H., Song, C. H., Seo, C. H., Kim, D. S., Park, I. S., Choi, K. S., Na, H. K., Chung, S. J., Lee, M. H. and Shim, C. K. (1998). Development of K-BE test^T^M, a computer program for the analysis of bioeqivalence, J. Kor. Pharm. Sci., 28, 223-229
  11. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Cham- bon, P. and Evans, R. M. (1995). The nuclear receptor super- family: the seconde decade. Cell, 83, 835-839
  12. Mollmann, H., Rohdewald, P., Schmidt, E. W., Salomon, V. and Derendorf, H. (1985). Pharmacokinetics of triamcinolone acetonide and its phosphate ester, Eur. J. Clin. Pharmacol., 29(1), 85-89
  13. Portner, M., Mollmann, H., Barth, J. and Rohdewald, P. (1988). Arzneim-forsch/Drug Res., 38, 838-840Pharmacokinetics of triamcinolone following oral application.
  14. Rubin, R. P. (1997). Chapter 62. Adrenocortical hormones and drugs affecting the adrenal cortex, In Modern Pharmacology with Cnlical Applications, Craig CR and Stitzel RE (ed). 5th ed. Little, Brown and Company: New York, 721-735
  15. Saito, Z., Amatzu, E., Ono, T, Hihumi, S., Mimou, T., Hashiba, T., Sakato, S., Miyamoto, M. and Takeda, R. (1979). The high- pressure liquid chromatography of corticoids. II. Analysis of synthetic corticoids in blood and urine. Nippon Naibunpi Gak- kai Zasshi 55(10), 1296-1306
  16. Schimmcr, B. P. and Parker, K. L. (2001). Chapter 60. ACTH; Adrenocortical steroids and their synthetic analogs, In Good- man and Gilmans The Pharmacologiocal Basis of Therapeu- tics. 10th ed., Hardman JG and Limbird LE (ed), McGraw- Hill, International Edition, 1649-1677
  17. Shargel, L. and Yu, A. B. C. (1993). Chapter 10. Bioavailability and bioequivalence. In Applied biopharmaceutics and Pharma- cokinetics, 3rd ed., Appleton & Lange, Nowwalk, USA, 193- 223
  18. Zelissen, P. M. J., Croughs, R. J. M., van Rijk, P. P. and Raymak- ers, J. A. (1994). Effects of glucocorticoid replcement therapy on bone mineral density in patients with Addison disease. Ann Intern. Med., 120, 207-210